Insider Selling: IDEXX Laboratories, Inc. (IDXX) Insider Sells $312,140.00 in Stock
IDEXX Laboratories, Inc. (NASDAQ:IDXX) insider Giovani Twigge sold 2,000 shares of the business’s stock in a transaction dated Thursday, November 30th. The shares were sold at an average price of $156.07, for a total value of $312,140.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.
Shares of IDEXX Laboratories, Inc. (IDXX) opened at $159.99 on Thursday. The stock has a market capitalization of $13,935.81, a PE ratio of 53.80, a PEG ratio of 2.42 and a beta of 0.42. IDEXX Laboratories, Inc. has a 52 week low of $113.92 and a 52 week high of $173.01. The company has a debt-to-equity ratio of -12.48, a quick ratio of 0.77 and a current ratio of 0.95.
IDEXX Laboratories (NASDAQ:IDXX) last announced its earnings results on Tuesday, October 31st. The company reported $0.79 earnings per share for the quarter, beating the consensus estimate of $0.74 by $0.05. IDEXX Laboratories had a negative return on equity of 336.64% and a net margin of 14.55%. The firm had revenue of $492.00 million during the quarter, compared to the consensus estimate of $492.94 million. During the same quarter in the prior year, the company earned $0.62 EPS. The firm’s revenue for the quarter was up 9.7% compared to the same quarter last year. research analysts expect that IDEXX Laboratories, Inc. will post 3.24 earnings per share for the current year.
Several research firms have recently issued reports on IDXX. Canaccord Genuity reiterated a “buy” rating and set a $180.00 price target on shares of IDEXX Laboratories in a research note on Friday, October 6th. Bank of America upgraded IDEXX Laboratories from a “neutral” rating to a “buy” rating and set a $175.00 price target for the company in a research note on Wednesday, August 23rd. Zacks Investment Research upgraded IDEXX Laboratories from a “hold” rating to a “buy” rating and set a $184.00 price target for the company in a research note on Tuesday, October 24th. Finally, Stifel Nicolaus reiterated a “buy” rating and set a $185.00 price target on shares of IDEXX Laboratories in a research note on Tuesday, October 24th. Two equities research analysts have rated the stock with a sell rating, one has issued a hold rating and five have given a buy rating to the company’s stock. IDEXX Laboratories presently has a consensus rating of “Hold” and a consensus target price of $173.67.
TRADEMARK VIOLATION NOTICE: This article was first reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this article on another domain, it was copied illegally and reposted in violation of U.S. & international trademark and copyright laws. The correct version of this article can be read at https://www.thecerbatgem.com/2017/12/07/insider-selling-idexx-laboratories-inc-idxx-insider-sells-312140-00-in-stock.html.
About IDEXX Laboratories
IDEXX Laboratories, Inc develops, manufactures and distributes products and provides services for the companion animal veterinary, livestock and poultry, dairy and water testing markets. The Company also sells a line of portable electrolytes and blood gas analyzers for the human point-of-care medical diagnostics market.
Receive News & Ratings for IDEXX Laboratories Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEXX Laboratories Inc. and related companies with MarketBeat.com's FREE daily email newsletter.